The results are excellent even when exposing the UBP-product to stress, this by exposing it to larger plasma volumes and higher flow rates than what is recommended for the product. 

The results show that the UBP-product effectively lowers the level of blood group antibodies (anti-A/B antibodies) to low levels. Important blood components such as total protein, albumin, glucose, immunoglobulins, and various antibodies specific to common pathogenic viruses were not significantly affected. 

The fact that the product has no significant effect on the total amount of antibodies in plasma nor affecting virus-specific antibodies is seen as potentially important for the manufacturing of covid-19 convalescent plasma and for preparation of immunoglobulins (IVIG) with reduced levels of anti-A/B antibodies.

On Friday, September 24, the transfusion unit at the University of Rochester will present their results of the UBP-product for the reduction of anti-A/B antibodies from blood group O whole blood. 


The information was submitted for publication, through the agency of the contact person, on September 22, 2021 09:00 CET.

Johan Nilsson, Interim CEO, Glycorex Transplantation AB.
 E-mail:, phone: 046-286 52 30

Brief information about the company
Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.